Articles tagged with Cytokine Receptors
Researchers found that immune molecule IL-17 influences brain regions to induce either anxiety in the amygdala or sociable behavior in the somatosensory cortex. This discovery highlights the interconnectedness of the immune and nervous systems.
Researchers aim to find a new treatment pathway for diabetic retinopathy by targeting the IL-6 protein. They suspect that selectively inhibiting trans-signaling while allowing cis-signaling will stop damage and restore balance in the retina.
Researchers used single-molecule microscopy and X-ray crystallography to discover that pathogenic JAK2 mutations utilize pseudokinase domain-mediated dimerization as a mechanism for activation. The study provides new insights into the molecular basis of JAK2 activation and its role in blood cancers.
Researchers from Osaka University have discovered a novel treatment strategy for cytokine storm, a serious inflammatory syndrome triggered by an infection or severe burn. The new approach involves blocking IL-6 receptor signaling with a short-term antibody, minimizing treatment side effects and preventing vascular damage.
Scientists at St. Jude Children's Research Hospital created a highly adaptable system to improve the safety and efficacy of immunotherapy for solid tumors. By adding modular chimeric cytokine receptors to CAR T cells, the therapy can target multiple types of cancer without generating significant toxicity.
Researchers have discovered a key mechanism involved in dental pulp inflammation and root apex damage, which could lead to the development of medications against bone loss due to endodontic infections. The study found that tumor necrosis factor-α receptor-1 (TNFR1) plays a crucial role in protecting teeth from inflammatory processes.
Researchers have developed a synthetic peptide that could help reduce vascular problems associated with acute respiratory distress syndrome in COVID-19. The peptide, called TIP, works by binding to a subunit of the epithelial sodium channel, which helps maintain barrier function and prevent damage from viral proteins.
Researchers found that Dectin-1 stimulation induced a unique immune signature in HIV-positive older adults, characterized by increased levels of IL-12, TNF-α, and IFN-α. This signature may contribute to the pro-inflammatory environment associated with HIV and aging.
Researchers have found that a prostate cancer drug called proxalutamide can block SARS-CoV-2 viral entry and reduce inflammation. The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.
Researchers identified a new class of molecules capable of preventing excessive inflammation in severe COVID-19. Blocking the link between peptide C5a and its cellular receptor reduced lung damage and other complications in mice. This finding suggests that antagonists of C5aR1 could be useful for treating severe COVID-19.
A groundbreaking study has uncovered potential treatments for inflammatory disorders by targeting specific receptors involved in the immune response. Researchers created mimetic peptides that successfully reduced inflammation in human immune cells and provided significant protection against toxic shock in mice.
COPD patients treated with dupilumab experienced rapid and sustained improvements in disease, as measured by reduced acute exacerbations, better lung function, and improved quality of life. This is the first biologic to show clinical outcomes improvement in COPD.
Researchers identified potential novel receptors for SARS-CoV-2 that utilize multiple receptors to facilitate its life cycle. The study reveals a strong correlation between tissue age-dependency and SARS-CoV-2 infection-induced receptor expression, with older adults being more susceptible to severe outcomes.
Researchers from ETH Zurich elucidated the structure and function of tryptophan C-mannosyltransferase (CMT), a glycosyltransferase enzyme involved in C-mannosylation. The study reveals the enzyme's novel mechanism, enabling precise understanding of protein sequences and sugar substrates.
Researchers at La Jolla Institute for Immunology have found that the inflammatory molecule LIGHT leads to airway remodeling and long-term breathing issues in severe asthma. Therapeutics targeting LIGHT could reverse airway and lung damage, offering a potential long-term treatment for asthma.
Researchers developed a fusion protein that selectively targets tumor neovasculature, inhibiting tumor growth in immunocompetent mice. The antibody-based delivery of engineered cytokines shows potential for improved therapeutic effects.
A team of MIT researchers has developed specialized proteins that can soak up excess cytokines, alleviating symptoms from coronavirus infection. The proteins, designed to mimic cytokine receptors, have shown promise in laboratory tests and are now being tested in human cells and animal models.
Scientists at the University of Göttingen have identified an alternative erythropoietin receptor, CRLF3, which triggers protective effects in humans without stimulating red blood cell production. This discovery offers new hope for treating neurodegenerative diseases such as Alzheimer's and Parkinson's.
Ozanimod demonstrated a significant reduction in new or enlarging T2 lesions over one year, as well as slowed brain volume loss, compared to Avonex in patients with relapsing multiple sclerosis. The findings pave the way for ozanimod to enter the New Drug Approval process with the FDA.
A high-risk subtype of Ph-like ALL is prevalent in adults with ALL, associated with a poor outcome. The study found that many patients may benefit from treatment with tyrosine kinase inhibitors, such as dasatinib and imatinib.
Researchers develop a novel approach to drug design using diabodies to tune cytokine receptor signaling. The method shows promise in targeting cancer cells and has the potential to reduce side effects by selectively blocking pathologic signals.
The IL-21 receptor plays a pivotal role in the Th2 immune response, which is often disrupted in chronic diseases. This receptor is essential for regulating T-cell function and cytokine production.
The Phase I/II study of NUVANCE in adult patients with moderate asthma demonstrated the potential of IL-4 inhibition to improve lung function and control asthma symptoms. Dr. Jonathan Corren and Dr. Jan Agosti presented results at the AAAAI Annual Meeting.